MedNous recently interviewed Professor Amit Nathwani, Chief Executive Officer of UCLTF portfolio company NovalGen. He shares his views for their article, ‘Bispecific antibody development gains momentum’.
Read the article here:
MedNous: published in the March 2021 edition of MedNous, a publication of Evernow Publishing Ltd.
We make UCL’s research physical and life sciences ideas happen.
